Immunoprevention for multiple myeloma using preclinical models
Official title: Preclinical studies for the immunoprevention of multiple myeloma
Funded at Mayo Clinic Arizona · NIH-11399807 · Data updated 2026-11-12
Researchers will study early-stage multiple myeloma using mouse models to test safe, low-risk prevention strategies for people at high risk of progression.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Arizona NIH-funded |
| Lab location | 1 site (Scottsdale, United States) |
| Project start | August 15, 2025 |
| Project end | May 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $704,622 |
| NIH project number | 5UG3CA290468-02 |
| Project ID | NIH-11399807 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with smoldering multiple myeloma at high risk of progression and who may benefit from early preventive approaches and future trials.
✕Less likely to help
Patients with established active multiple myeloma or those not at risk of progression may not benefit from this preclinical-focused effort.
What this research studies
This grant focuses on creating and using immunocompetent mouse models that mimic smoldering multiple myeloma progressing to full multiple myeloma. Researchers will test interventions, including immunomodulatory therapies, to see if they can delay or prevent progression. The goal is to identify safe approaches that could be translated to clinical trials for patients, especially those at higher risk and of African ancestry who are disproportionately affected. Work will also explore how the gut microbiome influences disease progression and response to treatment. The study is conducted at Mayo Clinic Arizona with a plan to compare cohorts across sites to strengthen findings.
Why it matters
Potential benefit: If successful, the work could lead to safer, earlier intervention strategies to delay or prevent progression to symptomatic myeloma for at-risk patients.
How similar studies have gone: Preclinical immunocompetent models have shown promise in reflecting human disease progression and drug responses, supporting translational potential.
Where this research is happening
-
Mayo Clinic Arizona
Scottsdale, United States Active
Researchers
- Principal investigator: Bergsagel, Peter Leif — Mayo Clinic Arizona
- Study coordinator: Bergsagel, Peter Leif
Related research
Other NIH-funded projects on the same topics.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
-
BCMA CAR-T enteritis: understanding immune toxicities in multiple myeloma
A broad study to uncover why some CAR-T cell treatments targeting BCMA cause severe intestinal inflammation in people with multiple myeloma.
-
Understanding Drug-Resistant Multiple Myeloma to Stop Relapse
Researchers are studying why some myeloma cells resist treatment and how to create new therapies to prevent relapse.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.